Ardelyx, Inc.

We are dedicated to improving the lives of patients by discovering, developing, and commercializing first-in-class targeted therapies that advance patient care. Our research expertise on biological mechanisms and pathways has enabled us to develop a pipeline of drug candidates designed to address important unmet clinical needs, including better management of complications related to kidney and cardiovascular diseases, with the goal of improving outcomes for this large population of underserved patients. Our lead candidate tenapanor, is a first-in-class, targeted, small molecule currently under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. We are also developing earlier-stage candidates that further leverage our discovery capabilities and deep understanding of transport mechanisms, targeting specific pharmacologic pathways. Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX. Tapping into the best talent on both coasts and everywhere in between, we maintain dual headquarters in the greater San Francisco and Boston biotech communities.